The global fiducial markers market is anticipated to reach USD 150.4 million by 2028, growing at a CAGR of over 4.0%. Increasing incidence of cancer such as breast, lung, and prostate cancer, along with the growing use of radiotherapy for oncology therapies is likely to show steady growth for fiducial markers in coming years.
PR.png)
Adroit Market Research report on global fiducial markers market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, challenges and regulatory scenario. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and positions the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global market have been studied in detail.
The global market is segmented on the basis of product, end user and application. The product segment is further broken down to gold, gold combination, polymer, other metal, liquid. In terms of application, the market is bifurcated into breast cancer, lung cancer, prostate cancer, head and neck cancer, and others. On the basis of modality, the market is segmented into CT/CBCT, MRI, ultrasound, and X-Ray.
Key players in the market include QlRad, Inc., QFIX, Boston Scientific Corp., CIVCO Radiotherapy, IZI Medical Products, Naslund Medical AB, Medtronic PLC, Nanovi A/S, Eckert & Ziegler, IBA Dosimetry GmbH, and many more among others.
Key segments of the global fiducial markers market
Product Overview, 2018-2028 (USD Million)
- Gold
- Gold Combination
- Polymer
- Other Metal
- Liquid
Modality Overview, 2018-2028 (USD Million)
- CT/CBCT
- MRI
- Ultrasound
- X-Ray
Application Overview, 2018-2028 (USD Million)
- Breast cancer
- Lung cancer
- Prostate cancer
- Head and neck cancer
- Other
End User Overview, 2018-2028 (USD Million)
- Hospitals
- Radiotherapy center
- Academic and research center
Regional Overview, 2018-2028 (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa